Posterior reversible encephalopathy syndrome (PRES) after combination chemotherapy for lymphoma.
Posterior reversible encephalopathy syndrome (PRES) is a serious neurologic disorder marked by acute neurologic symptoms and classic neuroimaging lesions. It occurs in the setting of certain medications and predisposing clinical conditions. We present a case of PRES in a patient with mantle cell lymphoma treated with systemic and intrathecal chemotherapy. The literature suggests a propensity for PRES to arise from the combination of malignancy, intensive induction chemotherapy, and intrathecal administration. PRES is an uncommon and underappreciated complication of certain chemotherapy regimens. The risk of PRES in this setting needs to be considered in managing patients with hematologic malignancies.
1Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA 2Department of Internal Medicine, Division of General Medicine, Emory University School of Medicine, Atlanta, GA.
Ambili
A
Ramachandran
Robin
R
Klein
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*